Recursion Pharmaceuticals is trading 5.37% up now at $3.73, appearing to benefit mainly from broader biotechnology strength.
- The sector is up 2.55%, while the stock extended its 10.97% gain on September 17.
- No clear company-specific announcement dated September 18 directly explains the move.
- Recent discussion has highlighted continued interest in Recursion’s clinical pipeline, cost reductions, and partnership milestones.